Delayed
Bombay S.E.
06:00:58 2024-07-16 am EDT
|
5-day change
|
1st Jan Change
|
17.17
INR
|
-1.27%
|
|
+1.60%
|
-0.92%
|
Fiscal Period: Marzo |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
509.3
|
428.1
|
844.1
|
646.4
|
422
|
331.4
|
Enterprise Value (EV)
1 |
573.9
|
507
|
929.6
|
740.2
|
449.4
|
352.1
|
P/E ratio
|
-47.5
x
|
-16.9
x
|
-42
x
|
-83.2
x
|
28.2
x
|
-46.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
82.6
x
|
21.2
x
|
59
x
|
4,983
x
|
1,880
x
|
1,527
x
|
EV / Revenue
|
93
x
|
25.2
x
|
64.9
x
|
5,706
x
|
2,001
x
|
1,623
x
|
EV / EBITDA
|
-50.9
x
|
-20.8
x
|
-42.5
x
|
-79.4
x
|
-112
x
|
-35.7
x
|
EV / FCF
|
-23
x
|
-13.7
x
|
-61.8
x
|
-112
x
|
-20.3
x
|
48.2
x
|
FCF Yield
|
-4.34%
|
-7.28%
|
-1.62%
|
-0.89%
|
-4.92%
|
2.07%
|
Price to Book
|
4.77
x
|
3.51
x
|
7.16
x
|
5.8
x
|
3.19
x
|
2.65
x
|
Nbr of stocks (in thousands)
|
11,059
|
13,809
|
14,809
|
14,809
|
14,809
|
14,809
|
Reference price
2 |
46.05
|
31.00
|
57.00
|
43.65
|
28.50
|
22.38
|
Announcement Date
|
8/27/18
|
9/3/19
|
12/2/20
|
8/20/21
|
8/25/22
|
9/6/23
|
Fiscal Period: Marzo |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
6.167
|
20.14
|
14.32
|
0.1297
|
0.2245
|
0.217
|
EBITDA
1 |
-11.27
|
-24.4
|
-21.86
|
-9.323
|
-4.025
|
-9.871
|
EBIT
1 |
-11.39
|
-24.59
|
-22.03
|
-9.444
|
-4.079
|
-9.908
|
Operating Margin
|
-184.73%
|
-122.05%
|
-153.83%
|
-7,279.69%
|
-1,816.47%
|
-4,565.9%
|
Earnings before Tax (EBT)
1 |
-11.11
|
-23.48
|
-20.53
|
-8.016
|
14.98
|
-7.072
|
Net income
1 |
-10.36
|
-22.31
|
-19.82
|
-7.767
|
14.98
|
-7.072
|
Net margin
|
-167.93%
|
-110.75%
|
-138.4%
|
-5,987.11%
|
6,673.12%
|
-3,258.9%
|
EPS
2 |
-0.9698
|
-1.833
|
-1.357
|
-0.5245
|
1.010
|
-0.4800
|
Free Cash Flow
1 |
-24.92
|
-36.92
|
-15.04
|
-6.599
|
-22.11
|
7.302
|
FCF margin
|
-404.12%
|
-183.26%
|
-105.02%
|
-5,086.95%
|
-9,846.31%
|
3,364.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/27/18
|
9/3/19
|
12/2/20
|
8/20/21
|
8/25/22
|
9/6/23
|
Fiscal Period: Marzo |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
64.6
|
79
|
85.5
|
93.8
|
27.3
|
20.7
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-5.731
x
|
-3.235
x
|
-3.913
x
|
-10.06
x
|
-6.786
x
|
-2.097
x
|
Free Cash Flow
1 |
-24.9
|
-36.9
|
-15
|
-6.6
|
-22.1
|
7.3
|
ROE (net income / shareholders' equity)
|
-7.62%
|
-14.6%
|
-12.4%
|
-5.02%
|
12.3%
|
-5.49%
|
ROA (Net income/ Total Assets)
|
-3.38%
|
-6.26%
|
-5.06%
|
-2.08%
|
-1.51%
|
-3.79%
|
Assets
1 |
306.5
|
356.6
|
391.8
|
374.1
|
-990.6
|
186.7
|
Book Value Per Share
2 |
9.660
|
8.840
|
7.960
|
7.530
|
8.930
|
8.450
|
Cash Flow per Share
2 |
0.2900
|
0.0200
|
0.0200
|
0.0100
|
0.0100
|
0
|
Capex
1 |
11.9
|
15.5
|
11.1
|
3.41
|
-
|
-
|
Capex / Sales
|
192.8%
|
76.95%
|
77.8%
|
2,630.97%
|
-
|
-
|
Announcement Date
|
8/27/18
|
9/3/19
|
12/2/20
|
8/20/21
|
8/25/22
|
9/6/23
|
|
1st Jan change
|
Capi.
|
---|
| -0.92% | 3.04M | | -16.94% | 8.48B | | +87.40% | 4.81B | | +16.31% | 2.99B | | -3.15% | 2.65B | | -2.10% | 2.02B | | -53.27% | 1.87B | | -12.97% | 1.58B | | +21.59% | 1.25B | | -47.96% | 1.06B |
Medical & Diagnostic Laboratories
|